Keyword Tag Sort by

Bcr-Abl News (4 articles)

Scientists discover how to beat resistance to standard leukaemia drug

Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according to research published in Cancer Cell*.The team carried out the research in CML cells....

Published on 9 December 2011, 13:23

Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in patients with newly diagnosed CML

Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the disease 24-month analysis confirms Tasigna induces deeper and more durable cytogenetic and molecular responses...

Published on 6 December 2010, 07:22

FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec®

Pivotal data from ENESTnd published in today's New England Journal of Medicine In head-to-head trial, Tasigna reduced leukemia-causing protein faster than Glivec, resulting in lower rates of cancer progression even as early as 12 months[1] Regulatory submissions under way...

Published on 18 June 2010, 04:57

Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia

. Tasigna surpassed Glivec in every measure of treatment efficacy designated in the trial including prevention of disease progression at 12 months[1] . At 12-month milestone, significantly fewer patients progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Glivec 400...

Published on 9 December 2009, 04:27